Santa Clara, CA and Penzberg, Germany 11/7/12—Agilent Technologies will be the exclusive provider of continued services to Roche NimbleGen customers as Roche phases out its NimbleGen microarray production and services. Roche and Agilent announced that customers can transition to Agilent arrays with minimal disruption for all applications because of the technologies’ similarities. “Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond,” stated Robert Schueren, vice president and general manager of Agilent’s Genomics Systems Division.